This legislation aims to update and extend the user fee program for over-the-counter (OTC) monograph drugs, which are non-prescription medications. Its primary goal is to ensure that the Food and Drug Administration (FDA) has the necessary funding to regulate and oversee these products effectively, thereby enhancing their quality and safety for consumers. Key provisions include the establishment of a structured fee system for fiscal years 2026 through 2030, with specific revenue targets and fee amounts outlined for each year.